Sequence Analysis of TNFRSF13b, Encoding TACI, in a Patient with Very Early Onset Inflammatory Bowel Disease: a Case Report

Authors

  • Jiaying Shen The Children’s Hospital, Zhejiang University School of Medicine

DOI:

https://doi.org/10.30564/jams.v1i4.290

Abstract

Very early onset inflammatory bowel disease (VEO-IBD), IBD diagnosed before 6 years of age, frequently presents with increased severity, aggressive progression, and often poor response to conventional treatments. Although the cause of IBD is generally considered to be intestinal immune dysfunction induced by polygenic mutations and environment and other factors, VEO-IBD has a stronger genetic susceptibility specifically the neonatal- or infantile-onset IBD. Herein we report compound heterozygous mutations in the tumor necrosis factor receptor superfamily member 13b (TNFRSF13B) gene in a 3-year-old male that was admitted to our hospital with lasted jaundice, repeated fever and diarrhea in May 2014 at 2-month-old. He was diagnosed with VEO-IBD based on clinical, laboratory and histopathological examination. However, he was unresponsive to the conventional therapy, including the nutritional support therapy, antibiotic and immunosuppressive treatment, and surgical release of neonatal intestinal obstruction. Novel compound heterozygous mutations, c.[365G>A];[452C>T](p.[R122Q];[P151L]), were discovered in TNFRSF13B, encoding TACI, for this patient.

Keywords:

VEO-IBD, TNFRSF13B, TACI, Treatment, Mutation

References

[1] Loddo I, Romano C. Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis[J]. Frontiers in immunology, 2015, 6:551.

[2] McGovern D, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases[J]. Gastroenterology, 2015, 149(5):1163-76.

[3] Liu JZ, Van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations[J]. Nat Genet, 2015, 47(9):979-86.

[4] Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease[J]. Gastroenterology, 2012, 143:285-8.

[5] Snapper SB. Very-Early-Onset Inflammatory Bowel Disease[J]. Gastroenterol Hepatol (N Y), 2015, 11(8):554-556.

[6] Glocker EO, Kotlarz D, Boztug K, et a1.Inflammatory bowel disease and mutations affecting the interleukin-10 receptor[J].N Engl J Med, 2009, 361(21): 2033-2045.

[7] Glocker EO,Frede N, Perro M, et a1.Infant colitis-it’s in the genes[J]. Lancet, 2010, 376(9748):1272.

[8] Worthey EA, Mayer AN, Syverson GD, et a1. Making a definitive diagnosis; successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease[J].Genet Med, 2011, 13(3):255-262.

[9] Blaydon DC,Biancheri P, Di WL, et a1.Inflammatory skin and bowel disease linked to Adaml7 deletion [J]. N Engl J Med, 2011, 365(16):1502-1508.

[10] Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn’s disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America[J]. J Pediatr Gastroenterol Nutr, 200, 44:653-674.

[11] Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells[J]. J Exp Med, 2005, 201:35-9.

[12] Sakurai D, Kanno Y, Hase H, et al. TACI attenuates antibody production costimulated by BAFF-R and CD40[J]. Eur J Immunol, 2007, 37:110-8.

[13] Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL[J]. Nat Immunol, 2002, 3: 822-9.

[14] Jinqiu Jiang, Maozhi Tang. Research progress of common variable immunodeficiency[J]. Journal of Pediatric Pharmacy, 2015, 21:7.

[15] Sazzini M, Zuntini R, Farjadian S. An evolutionary approach to the medical implications of the tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) gene[J]. Genes and immunity 2009, 10(6):566-78.

[16] Castigli E, Wilson SA, Gariby L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency[J]. Nat Genet 2005, 37:829-34.

[17] . Salzer U, Chapel HM, Webster ADB, et al. Mutations in TNFRSF13B encoding

[18] TACI are associated with common variable immunodeficiency in humans[J]. Nat Genet 2005, 37:820-8.

[19] Berglund LJ, Jones GJ, Murali R, et al. TACI mutation with invasive polyclonal CD81 T-cell lymphoproliferation in a patient with common variable immunodeficiency[J]. J Allergy Clin Immunol, 2006, 117(4):870-877.

[20] Gu Yan, Ran Zhihua. Research progress of bone marrow stem cells in the treatment of inflammatory bowel disease[J]. Journal of Gastroenterology and Hepatology, 2009, 18(10):889-892.

Downloads

Issue

Vol. 1 , Iss. 4 (November 2018)

Article Type

Research Article

License

Copyright and Licensing

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

Journal of Advances in Medicine Science publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Advances in Medicine Science agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.

License Policy for Reuse of Third-Party Materials

If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.

Journal Policies on Data Sharing

We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.